StockIQpro
NASDAQ:JANX

Janux Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Janux Therapeutics, Inc.'s revenue fell 5.6% in fiscal 2025 to $10.0M while operating margin fell to −1576.7%, its lowest in 5 years. Free cash flow was −$83.3M, −832.8% of revenue, and the diluted share count rose 15.3%.Summary generated from Janux Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$10.0M
Revenue growth−5.6%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−1576.7%
Net margin−1136.3%
ROICn/a
Return on equity−11.5%
Debt / equityn/a
Free cash flow−$83.3M
FCF margin−832.8%
Share count change+15.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue4981110
Operating income−33−67−73−99−158
Net income−33−63−58−69−114
Free cash flow−18−49−52−44−83

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations